METASTATIC PROSTATE CANCER

This study tests whether adding the immune-boosting drug Sipuleucel-T (Provenge) to standard hormone therapy can help men with advanced prostate cancer that is no longer responding to hormones alone. The trial involves 26 participants who will receive either Sipuleucel-T alone or…

This early-stage trial tests a new drug called ARX517, which is designed to find and kill prostate cancer cells while sparing healthy ones. It is being tested alone or with other standard treatments in 183 men with prostate cancer that has spread to other parts of the body. The m…

This study tests a new drug called AZD5305 combined with standard hormone therapies in 174 men with metastatic prostate cancer. The goal is to see if the combination is safe and can help control the disease. Participants take daily pills, and researchers monitor side effects and …

This phase II trial tests whether adding precise radiation (SBRT) to the hormone therapy darolutamide can delay cancer progression in men with castration-resistant prostate cancer that has only a few new spots of growth. The study involves 66 participants and measures how long it…

This early-phase trial tests whether combining two oral targeted drugs, talazoparib and tazemetostat, is safe and can shrink or slow the growth of metastatic castration-resistant prostate cancer (mCRPC). About 35 adults with advanced prostate cancer that has spread and is no long…

This study tests whether adding the immunotherapy drug atezolizumab and targeted radiation (SBRT) to standard hormone therapy (abiraterone, prednisone, and leuprolide) is safe and works better for men with newly diagnosed metastatic prostate cancer that hasn't been treated yet. T…

This study looks at men whose prostate cancer has come back in a few spots (oligometastatic) and who have certain gene mutations. It compares standard care (hormone therapy plus radiation) against the same treatment plus a 6-month course of two drugs (niraparib and abiraterone wi…

This early-phase trial tests a new type of immune cell therapy (PSMA-UCAR T cells) in 3 men with advanced prostate cancer that no longer responds to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants must have me…

This early-stage trial tests whether combining a targeted radiation drug (177Lu-PSMA-617) with chemotherapy (carboplatin) is safe and can shrink tumors in men with metastatic castration-resistant prostate cancer. About 37 men will receive the combination to find the best dose and…

This study tests a combination of four drugs (nivolumab, ipilimumab, cabazitaxel, and carboplatin) in 41 men with a hard-to-treat form of prostate cancer. The goal is to see if this mix can slow or stop cancer growth. Participants receive up to 10 cycles of the combo, then contin…

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This study looks at whether surgically removing the prostate, along with hormone therapy and possibly chemotherapy, can help men whose prostate cancer has already spread. About 190 men with newly diagnosed stage IV prostate cancer will be randomly assigned to get either standard …

This phase 3 trial tests whether giving denosumab every 12 weeks instead of every 4 weeks can still prevent bone complications (like fractures or spinal cord compression) in people with metastatic breast or prostate cancer. About 1,380 participants with bone metastases will be ra…

This phase 3 study tests whether combining two drugs—cabozantinib (a targeted therapy) and atezolizumab (an immunotherapy)—works better than standard hormone therapy for men with metastatic castration-resistant prostate cancer that has progressed after one prior hormone treatment…

This study looks at whether adding a high-precision type of radiation called SBRT to usual cancer treatments (like hormone therapy or chemo) can delay cancer growth in people with breast, lung, or prostate cancer that has spread to 1 to 5 bones. About 168 adults aged 18-75 with g…

This phase 2 study is testing a combination of two drugs, SKB264 and pembrolizumab (Keytruda), in 240 people with certain advanced solid tumors, including cervical, urothelial, ovarian, prostate, and endometrial cancers. The goal is to see if the combination is safe and effective…

This study compares a new radioactive tracer called 18F-DCFPyL with standard tracers to see if it can better detect where prostate cancer has spread in the body. About 96 men with metastatic prostate cancer will receive both tracers and undergo PET/CT scans. The goal is to measur…

This phase 2 trial tests whether a radioactive tracer called 18F-DCFPyL can improve PET/CT scans for men with high-risk or recurrent prostate cancer. About 360 men will receive the tracer and undergo imaging to see if it more accurately finds cancer outside the prostate or after …

This study is testing a new imaging method called Cerenkov luminescence imaging, which uses light naturally given off by certain radioactive substances used in standard cancer scans. Researchers want to see if this technique can take clear pictures of thyroid cancer and tumors th…

This early-phase trial tests TRDC002, a radioactive tracer that attaches to PSMA proteins on prostate cancer cells, to improve PET/CT imaging in patients whose cancer has returned or spread. Six adults with PSMA-positive recurrent or metastatic prostate cancer will receive a sing…

This study is testing whether a type of PET scan called PSMA PET is more accurate than standard scans (like CT or bone scans) for monitoring prostate cancer. About 58 men with progressive prostate cancer will receive an injection of a radioactive tracer and then undergo PET/CT im…

This study tests whether a structured home-based exercise program combining strength and aerobic training can improve quality of life, fitness, and immune function in 150 men with prostate cancer. Participants are randomly assigned to either the exercise program or usual care. Th…

This study tests whether a personalized 4-week exercise program can improve quality of life and physical function in men with metastatic prostate cancer who are receiving radiation therapy. Eighty participants will either exercise or not, and researchers will track changes in wel…

This study aimed to see if a 12-week supervised exercise program could improve quality of life and physical fitness in men with advanced prostate cancer receiving hormone therapy. Participants would have been randomly assigned to either the supervised program or usual care with e…

This study tests whether an extra meeting with a team of doctors, a palliative care specialist, and a psychologist can help patients with advanced cancer feel less torn about their next treatment. 62 adults with metastatic lung, breast, colon, ovarian, or prostate cancer who need…

This study examines 15 proteins on prostate cancer cells from 1,600 patients to see which ones are common and whether they relate to survival. Researchers will analyze stored tissue samples and collect new ones from men with advanced cancer. The goal is to understand these protei…

This study, called PARADIGM, is not testing a new drug. Instead, it looks at whether analyzing DNA from a blood sample can tell doctors which standard treatment—like hormone therapy or chemotherapy—will work best for a patient with metastatic prostate cancer. Researchers will tak…

This observational study looks at why hormone therapy eventually stops working in advanced prostate cancer. Researchers will take tumor samples from 30 patients before and during treatment to study changes in immune cells and cancer markers. The goal is to find early signs of res…

This study explores whether special PET scans (PSMA-PET) can better track how well treatment is working in men with metastatic hormone-sensitive prostate cancer. Twenty participants will receive standard care and undergo scans before and after 6 months of treatment. The goal is t…

This study looks at whether a blood test (liquid biopsy) can find cancer mutations as well as the standard tissue biopsy. Researchers will compare the two methods in 1,500 advanced cancer patients to see if the blood test helps doctors choose better treatments and saves money. Th…